PubMed HealthSearch

Biomedical subjects

J A Aitken

Publications and source records attributed to J A Aitken.

4 recordsLinked to original sources

Role of fibronectin in the organisation of the cytoskeleton during the spreading of rat mammary epithelial cells.

The correlation between the extracellular deposition of fibronectin and the development of the actin-containing cytoskeleton was studied during the attachment and spreading of the rat mammary epithelial cell line Rama 25. During the initial phase of cell spreading, actin is localised in peripheral microfilament bundles. As cell spreading increases, the peripheral ring is displaced towards the perinuclear region. Fibronectin, deposited beneath the basal surface, co-localises with the actin-containing peripheral ring. The peripheral ring subsequently disappears and is replaced by a system of radial microfilaments that extend from the perinuclear region to the cell periphery. At this stage, there is no correlation between the distribution of fibronectin and actin. As cells form colonies, radial microfilament bundles are replaced by peripheral microfilament bundles which do not co-localise with fibronectin. Cells at the edges of colonies extend lamellae that contain microfilament stress fibres. In these structures there is co-localisation of actin, fibronectin and the a5 beta 1-integrin fibronectin receptor.

Actins

Diagnosis and management of parkinsonism in the elderly.

Of 123 patients with parkinsonism attending a department of medicine for the elderly who were assessed, 73% were thought to have idiopathic Parkinson's disease, and 91% of these cases and 52% of the remaining cases had a history of rest tremor; 34% of all cases were demented. The prevalence of dementia did not correlate with the duration of disease. Demented patients with presumed idiopathic Parkinson's disease were not distinguishable from non-demented by duration of disease, presence of a history of rest tremor or use of L-dopa. Eighty-eight per cent of non-demented patients but only 44% of demented patients were thought to have responded to L-dopa. Lower doses of L-dopa were used than are conventional with younger patients.

Age Factors